Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.77 |
| ▸ | RAB9A | P51151 | 6/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365355 | 1.00 | NPC1 (0.77) | NPC1RAB9APOLBALDH1A1GAA | |
| SCHEMBL3366005 | 1.00 | NPC1 (0.77) | NPC1RAB9APOLBALDH1A1GAA | |
| SCHEMBL6271278 | 0.89 | NPC1 (0.77) | NPC1RAB9APOLBALDH1A1GAA | |
| SCHEMBL3364189 | 0.89 | ALDH1A1 (0.73) | NPC1RAB9APOLBALDH1A1GAA | |
| SCHEMBL3364183 | 0.89 | ALDH1A1 (0.73) | NPC1RAB9APOLBALDH1A1GAA | |
| SCHEMBL3367093 | 0.89 | ALDH1A1 (0.66) | NPC1RAB9APOLBALDH1A1GAA | |
| SCHEMBL3367101 | 0.89 | ALDH1A1 (0.66) | NPC1RAB9APOLBALDH1A1GAA | |
| SCHEMBL3363108 | 0.88 | NPC1 (0.78) | NPC1RAB9APOLBALDH1A1KMT2A | |
| SCHEMBL3363165 | 0.88 | NPC1 (0.78) | NPC1RAB9APOLBALDH1A1KMT2A | |
| SCHEMBL3365275 | 0.88 | NPC1 (0.78) | NPC1RAB9APOLBALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542970-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-1542969-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-03-03 | — | — | EP | disclosed |
| US-20070032542-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | IDING HANS | 2007-02-08 | — | — | US | disclosed |
| US-7151111-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-7148362-B2 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7122562-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | IDING HANS | 2006-06-08 | — | — | US | disclosed |
| EP-1664323-A1 | ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| US-7037935-B2 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1542969-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| EP-1542970-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005026373-A1 | ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| US-20050065204-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004026825-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026827-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | NPC1 1929/4885RAB9A 1750/4885POLB 90/4885 |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | MAOA, MAOB, PNPO | NPC1 3213/4885RAB9A 1847/4885POLB 368/4885 |
| US-20050065204-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | MAOB, MAOA, CYP1B1 | NPC1 3769/4885RAB9A 1445/4885POLB 89/4885 |
| US-20070032542-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | MAOB, MAOA, CYP1B1 | NPC1 3769/4885RAB9A 1445/4885POLB 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.